Table 6—

Initial antimicrobial treatment in patients with community-acquired pneumonia

Non-ICU patientsAetiologyp-value
WithWithout
Patients n10273
Monotherapy13 (13)15 (21)0.165
 Aminopenicillin120.376
 Aminopenicillin±β-lactamase inhibitor50.007
 Macrolide110.811
 Cephalosporin III1170.797
Dual combination therapy88 (86)58 (79)0.231
 Cephalosporin III+macrolide80500.138
 Cephalosporin III+clindamycin560.372
 Cephalosporin IV+macrolide110.811
 Cephalosporin IV+aminoglycoside110.811
 Carbapenem+aminoglycoside10.396
Triple combination therapy1 (1)0.396
 Cephalosporin III+macrolide+aminoglycoside10.396
ICU patients n209
Dual combination therapy16 (80)6 (67)0.437
 Cephalosporin III+macrolide1460.857
 Cephalosporin+clindamycin20.325
Triple combination therapy4 (20)3 (33)0.437
 Cephalosporin III+macrolide+aminoglycoside210.927
 Cephalosporin III+macrolide+clindamycin110.547
 Cephalosporin III+macrolide+vancomycin10.494
Carbapenem+macrolide+aminoglycoside10.129
  • Data are presented as n (%) or n. Data are reported separately for patients with and without definite aetiology and according to intensive care unit admission (ICU). The p-values were calculated using a Chi-squared test